The next major event isn't going to be more clinical trial results. We've just had a clinical trial result and no other clinical trials are underway.
The next major event will be a licensing agreement for AML in a geographic region, including some cash upfront.
This will happen because:
* the AML proofs of concept are now sufficiently complete
* RAC can't perform a loaves and fishes miracle; the cardioprotection and FTO programmes need more cash
* the current SP isn't conducive to a CR.
Why Analysts Believe RAC is “Highly Undervalued”, page-83
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
